Patents by Inventor Yoshikuni Nakamura
Yoshikuni Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240089567Abstract: There is provided an imaging device including a pixel array unit (300) configured by arraying, in a row direction and a column direction, a plurality of pixels (304) of five or more types in which wavelength bands of detectable light are different in stages. The plurality of pixels are arrayed such that, at points having any spatial phases on the pixel array unit, mixed spectral characteristics obtained by mixing spectral characteristics of a predetermined number of pixels around the points are substantially same.Type: ApplicationFiled: February 18, 2022Publication date: March 14, 2024Inventors: Seichi Otsuki, Shigeki Nakamura, Yoshikuni Nomura
-
Publication number: 20220283987Abstract: Whether a document file is tampered and the like can be determined without imposing a burden on a user. A hash value calculation unit 103 adds contents of update to an original document as incremental update in order of update, and calculates a hash value of the document file for each of the original document and a document for adding the updated content and a hash value of a document file the hash value and the document file ID, identifying the document file, of which are registered in a blockchain network. An ID acquisition unit 102 acquires the document file ID identifying a received document file, from the document file. A hash value acquisition unit 105 acquires the hash value stored in the latest block among blocks storing the document file IDs from the blockchain network. A tampering determination unit 106 determines whether the document file is tampered by determining whether the hash value calculated and the hash value acquired from the blockchain network 300 match.Type: ApplicationFiled: November 26, 2020Publication date: September 8, 2022Applicant: SKYCOM CORPORATIONInventor: YOSHIKUNI NAKAMURA
-
Publication number: 20180177766Abstract: Provided are a novel pharmaceutical use of PPAR? agonist such as a therapeutic agent for neurotrophic keratopathy, an improving agent for decrease of corneal sensitivity and the like, each containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: June 9, 2016Publication date: June 28, 2018Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shinya KOBAYASHI, Yoshikuni NAKAMURA, Takeshi TARUI, Tomoyuki WADA
-
Patent number: 9463185Abstract: A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.Type: GrantFiled: June 27, 2014Date of Patent: October 11, 2016Assignees: SENJU PHARMACEUTICAL CO., LTD., NIPPON CHEMIPHAR CO., LTD.Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Patent number: 9096538Abstract: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR? or ? agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR? or ? agonist as an active ingredient.Type: GrantFiled: February 28, 2012Date of Patent: August 4, 2015Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Publication number: 20140343109Abstract: Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.Type: ApplicationFiled: June 27, 2014Publication date: November 20, 2014Inventors: Yoshikuni NAKAMURA, Ikuko HANANO, Jun INOUE
-
Patent number: 8802705Abstract: Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.Type: GrantFiled: May 20, 2008Date of Patent: August 12, 2014Assignees: Senju Pharmaceutical Co., Ltd., Nippon Chemiphar Co., Ltd.Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Publication number: 20120270910Abstract: Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoroethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.Type: ApplicationFiled: May 20, 2008Publication date: October 25, 2012Applicants: SENJU PHARMACEUTICAL CO., LTD., NIPPON CHEMIPHAR CO., LTD.Inventors: Yoshikuni NAKAMURA, Ikuko HANANO, Jun INOUE
-
Publication number: 20120220612Abstract: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR? or ? agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR? or ? agonist as an active ingredient.Type: ApplicationFiled: February 28, 2012Publication date: August 30, 2012Inventors: Yoshikuni NAKAMURA, Ikuko Hanano, Jun Inoue
-
Patent number: 8148389Abstract: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR? or ? agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR? or ? agonist as an active ingredient.Type: GrantFiled: November 27, 2006Date of Patent: April 3, 2012Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Publication number: 20110212899Abstract: It is intended to provide an agent for promoting corneal neuritogenesis containing PACAP, a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, an agent for promoting corneal neuritogenesis aiming at improving corneal sensitivity, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal neuritogenesis. This agent for promoting corneal neuritogenesis is useful as a drug for ameliorating reduction in corneal sensitivity following corneal surgeries such as laser keratonomy (LASIK) and corneal grafting or cataract surgery, reduction in corneal sensitivity accompanying corneal neurodegeneration and dry eye symptom and corneal epithelial injury accompanying such reduction in corneal sensitivity.Type: ApplicationFiled: April 21, 2005Publication date: September 1, 2011Inventors: Yoshiko Takayama, Yoshikuni Nakamura, Yutaka Inoue, Chiho Yabuta, Mitsuyoshi Azuma, Satomi Onoue
-
Patent number: 7956072Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.Type: GrantFiled: November 3, 2008Date of Patent: June 7, 2011Assignees: Senju Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma CorporationInventors: Yoshiko Takayama, Yoshikuni Nakamura, Jun Inoue, Mitsuyoshi Azuma
-
Publication number: 20100190833Abstract: Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.Type: ApplicationFiled: May 20, 2008Publication date: July 29, 2010Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Publication number: 20090306111Abstract: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR? or ? agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR? or ? agonist as an active ingredient.Type: ApplicationFiled: November 27, 2006Publication date: December 10, 2009Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Publication number: 20090118322Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.Type: ApplicationFiled: November 3, 2008Publication date: May 7, 2009Inventors: Yoshiko Takayama, Yoshikuni Nakamura, Jun Inoue, Mitsuyoshi Azuma
-
Patent number: 7485654Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.Type: GrantFiled: June 3, 2005Date of Patent: February 3, 2009Assignees: Senju Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma CorporationInventors: Yoshiko Takayama, Yoshikuni Nakamura, Jun Inoue, Mitsuyoshi Azuma
-
Publication number: 20070093513Abstract: The present invention provides a novel pharmaceutical agent for recovering corneal sensitivity after corneal surgery and improving symptoms of dry eye. This pharmaceutical agent is useful for improving decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as post-cataract operation, post-LASIK operation, post-PRK operation, postkeratoplasty operation, neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like, since it contains a Rho protein inhibitor.Type: ApplicationFiled: April 16, 2004Publication date: April 26, 2007Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Yoshiko Takayama, Yoshikuni Nakamura, Jun Inoue, Mitsuyoshi Azuma
-
Publication number: 20060252765Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.Type: ApplicationFiled: June 3, 2005Publication date: November 9, 2006Inventors: Yoshiko Takayama, Yoshikuni Nakamura, Jun Inoue, Mitsuyoshi Azuma
-
Publication number: 20060234922Abstract: The present invention provides a new type of pharmaceutical agent that recovers corneal sensitivity after corneal surgery or improves the condition of dry eye. Application of a somatostatin receptor agonist is expected to provide an improvement effect on decreased corneal sensitivity after cataract surgery or LASIK surgery, decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like.Type: ApplicationFiled: October 22, 2003Publication date: October 19, 2006Inventors: Yoshiko Takayama, Yoshikuni Nakamura, Jun Inoue, Mitsuyoshi Azuma
-
Publication number: 20060094775Abstract: The present invention provides a pharmaceutical agent capable of effectively treating corneal ulcer, more particularly, a therapeutic agent for corneal ulcer, which contains triptolide or a derivative thereof or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 27, 2004Publication date: May 4, 2006Inventors: Teruo Nishida, Yoshikuni Nakamura